Switch to:
Also traded in: Argentina, Brazil, Chile, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.46
ABT's Cash to Debt is ranked lower than
78% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ABT: 0.46 )
Ranked among companies with meaningful Cash to Debt only.
ABT' s Cash to Debt Range Over the Past 10 Years
Min: 0.05  Med: 0.29 Max: 1.28
Current: 0.46
0.05
1.28
Equity to Asset 0.52
ABT's Equity to Asset is ranked lower than
67% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ABT: 0.52 )
Ranked among companies with meaningful Equity to Asset only.
ABT' s Equity to Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.44 Max: 0.59
Current: 0.52
0.37
0.59
Interest Coverage 15.11
ABT's Interest Coverage is ranked lower than
66% of the 192 Companies
in the Global Medical Devices industry.

( Industry Median: 45.13 vs. ABT: 15.11 )
Ranked among companies with meaningful Interest Coverage only.
ABT' s Interest Coverage Range Over the Past 10 Years
Min: 4.91  Med: 11.51 Max: 17.59
Current: 15.11
4.91
17.59
F-Score: 5
Z-Score: 3.53
M-Score: -2.40
WACC vs ROIC
11.41%
72.32%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 13.64
ABT's Operating margin (%) is ranked higher than
80% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 2.61 vs. ABT: 13.64 )
Ranked among companies with meaningful Operating margin (%) only.
ABT' s Operating margin (%) Range Over the Past 10 Years
Min: 9.09  Med: 16.06 Max: 20.28
Current: 13.64
9.09
20.28
Net-margin (%) 12.00
ABT's Net-margin (%) is ranked higher than
80% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 0.86 vs. ABT: 12.00 )
Ranked among companies with meaningful Net-margin (%) only.
ABT' s Net-margin (%) Range Over the Past 10 Years
Min: 7.64  Med: 13.54 Max: 21.68
Current: 12
7.64
21.68
ROE (%) 11.34
ABT's ROE (%) is ranked higher than
74% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 0.98 vs. ABT: 11.34 )
Ranked among companies with meaningful ROE (%) only.
ABT' s ROE (%) Range Over the Past 10 Years
Min: 9.78  Med: 20.51 Max: 28.49
Current: 11.34
9.78
28.49
ROA (%) 5.83
ABT's ROA (%) is ranked higher than
70% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: -0.34 vs. ABT: 5.83 )
Ranked among companies with meaningful ROA (%) only.
ABT' s ROA (%) Range Over the Past 10 Years
Min: 4.68  Med: 8.77 Max: 12.12
Current: 5.83
4.68
12.12
ROC (Joel Greenblatt) (%) 30.58
ABT's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 4.07 vs. ABT: 30.58 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ABT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 22.28  Med: 44.88 Max: 65.75
Current: 30.58
22.28
65.75
Revenue Growth (3Y)(%) -18.50
ABT's Revenue Growth (3Y)(%) is ranked lower than
82% of the 234 Companies
in the Global Medical Devices industry.

( Industry Median: 3.70 vs. ABT: -18.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ABT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -18.8  Med: 8.30 Max: 12.6
Current: -18.5
-18.8
12.6
EBITDA Growth (3Y)(%) -19.20
ABT's EBITDA Growth (3Y)(%) is ranked lower than
83% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. ABT: -19.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ABT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -21.2  Med: 4.90 Max: 31.8
Current: -19.2
-21.2
31.8
EPS Growth (3Y)(%) -22.90
ABT's EPS Growth (3Y)(%) is ranked lower than
82% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 2.60 vs. ABT: -22.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ABT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -28.1  Med: 4.20 Max: 48.8
Current: -22.9
-28.1
48.8
» ABT's 10-Y Financials

Financials (Next Earnings Date: 2016-07-20)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ABT Guru Trades in Q2 2015

Ray Dalio 28,457 sh (New)
Joel Greenblatt 1,043,293 sh (+2409.54%)
Paul Tudor Jones 13,700 sh (+47.31%)
First Eagle Investment 5,916,570 sh (+15.05%)
Ken Fisher 14,994 sh (+14.50%)
John Buckingham 91,559 sh (+0.72%)
Murray Stahl 18,603 sh (unchged)
Robert Bruce 230,915 sh (unchged)
Louis Moore Bacon 300,000 sh (unchged)
Westport Asset Management 200,000 sh (unchged)
Tom Russo 85,400 sh (unchged)
Vanguard Health Care Fund 7,591,400 sh (unchged)
George Soros 602,181 sh (unchged)
Jim Simons Sold Out
Jeff Auxier 77,821 sh (-0.06%)
PRIMECAP Management 17,737,310 sh (-0.16%)
Richard Pzena 6,340,115 sh (-0.53%)
Diamond Hill Capital 8,062,685 sh (-0.55%)
Dodge & Cox 31,268 sh (-2.49%)
Mairs and Power 341,838 sh (-3.36%)
Mario Gabelli 61,032 sh (-6.52%)
Pioneer Investments 1,861,927 sh (-6.71%)
Robert Olstein 159,000 sh (-11.17%)
Jeremy Grantham 9,499,219 sh (-11.45%)
» More
Q3 2015

ABT Guru Trades in Q3 2015

John Hussman 3,000 sh (New)
Jim Simons 1,348,400 sh (New)
Paul Tudor Jones 59,714 sh (+335.87%)
Ray Dalio 82,457 sh (+189.76%)
Joel Greenblatt 1,455,289 sh (+39.49%)
George Soros 731,481 sh (+21.47%)
Murray Stahl 21,503 sh (+15.59%)
First Eagle Investment 6,825,289 sh (+15.36%)
Robert Olstein 176,000 sh (+10.69%)
Diamond Hill Capital 8,385,413 sh (+4.00%)
Ken Fisher 15,254 sh (+1.73%)
Jeff Auxier 78,922 sh (+1.41%)
John Buckingham 91,905 sh (+0.38%)
Tom Russo 85,400 sh (unchged)
Westport Asset Management 200,000 sh (unchged)
Robert Bruce 230,915 sh (unchged)
David Carlson 600,000 sh (unchged)
Dodge & Cox 30,268 sh (-3.20%)
PRIMECAP Management 16,677,764 sh (-5.97%)
Mairs and Power 319,343 sh (-6.58%)
Vanguard Health Care Fund 6,938,700 sh (-8.60%)
Richard Pzena 5,188,346 sh (-18.17%)
Jeremy Grantham 6,469,218 sh (-31.90%)
Pioneer Investments 1,213,173 sh (-34.84%)
Mario Gabelli 17,625 sh (-71.12%)
» More
Q4 2015

ABT Guru Trades in Q4 2015

Robert Olstein 201,000 sh (+14.20%)
Ken Fisher 17,286 sh (+13.32%)
Murray Stahl 22,503 sh (+4.65%)
Diamond Hill Capital 8,621,765 sh (+2.82%)
Robert Bruce 230,915 sh (unchged)
Mario Gabelli 17,625 sh (unchged)
Jeff Auxier 78,922 sh (unchged)
Westport Asset Management 200,000 sh (unchged)
Tom Russo 85,400 sh (unchged)
David Carlson 600,000 sh (unchged)
Dodge & Cox 30,268 sh (unchged)
Spiros Segalas 9,871,440 sh (unchged)
John Hussman Sold Out
Jim Simons Sold Out
Pioneer Investments 1,212,972 sh (-0.02%)
Mairs and Power 318,918 sh (-0.13%)
PRIMECAP Management 16,643,039 sh (-0.21%)
John Buckingham 91,506 sh (-0.43%)
First Eagle Investment 6,671,344 sh (-2.26%)
Richard Pzena 4,861,129 sh (-6.31%)
George Soros 664,181 sh (-9.20%)
Jeremy Grantham 5,653,313 sh (-12.61%)
Vanguard Health Care Fund 6,027,260 sh (-13.14%)
Ray Dalio 38,857 sh (-52.88%)
Paul Tudor Jones 13,100 sh (-78.06%)
Joel Greenblatt 98,838 sh (-93.21%)
» More
Q1 2016

ABT Guru Trades in Q1 2016

Joel Greenblatt 861,862 sh (+771.99%)
Diamond Hill Capital 10,198,087 sh (+18.28%)
First Eagle Investment 7,507,515 sh (+12.53%)
Robert Olstein 220,000 sh (+9.45%)
Murray Stahl 22,778 sh (+1.22%)
PRIMECAP Management 16,812,839 sh (+1.02%)
Mairs and Power 319,391 sh (+0.15%)
Vanguard Health Care Fund 6,027,260 sh (unchged)
Robert Bruce 230,915 sh (unchged)
David Carlson 600,000 sh (unchged)
Westport Asset Management 200,000 sh (unchged)
Paul Tudor Jones Sold Out
Jeff Auxier 78,672 sh (-0.32%)
Pioneer Investments 1,201,725 sh (-0.93%)
Dodge & Cox 29,268 sh (-3.30%)
Richard Pzena 4,642,170 sh (-4.50%)
John Buckingham 87,087 sh (-4.83%)
Ken Fisher 15,413 sh (-10.84%)
Mario Gabelli 13,695 sh (-22.30%)
Jeremy Grantham 3,713,180 sh (-34.32%)
George Soros 419,181 sh (-36.89%)
Ray Dalio 11,400 sh (-70.66%)
Tom Russo 20,400 sh (-76.11%)
Spiros Segalas 9,668,976 sh (-2.05%)
» More
» Details

Insider Trades

Latest Guru Trades with ABT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NYSE:SYK, NYSE:BSX, NAS:ISRG, NYSE:ZBH, NYSE:STJ, NYSE:EW, OTCPK:SNNUF, OTCPK:SONVY, NYSE:VAR, NYSE:TFX, NAS:ALGN, OTCPK:SDMHF, OTCPK:WILYY, OTCPK:CHEOY, NAS:ABMD, OTCPK:FSPKF, NAS:NUVA, NAS:IART, OTCPK:EKTAY, OTCPK:GGNDF » details
Traded in other countries:ABT.Argentina, ABTT34.Brazil, ABT.Chile, ABL.Germany, ABT.Mexico, ABT.Switzerland, ABT.UK,
Abbott Laboratories discovers, develops, manufactures and sells health care products. Its products include branded generic pharmaceuticals manufactured internationally, marketed and sold outside the United States.

Abbott Laboratories is an Illinois corporation, incorporated in 1900. The Company discovers, develops, manufactures and sells health care products. Its services are sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians' offices and government agencies internationally. Its segments are Established Pharmaceutical Products, Nutritional Products, Diagnostic Products and Vascular Product. The Established Pharmaceutical Products is engaged in the International sales of various branded generic pharmaceutical products. Nutritional Products sells broad line of adult and pediatric nutritional products internationally. Diagnostic Products sells diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. This segment also includes Core Laboratories Diagnostics, Molecular Diagnostics, Point of Care and Ibis diagnostic divisions. Vascular Products sells coronary, endovascular, structural heart, vessel closure and other medical device products.

Ratios

vs
industry
vs
history
P/E(ttm) 23.18
ABT's P/E(ttm) is ranked higher than
58% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 26.63 vs. ABT: 23.18 )
Ranked among companies with meaningful P/E(ttm) only.
ABT' s P/E(ttm) Range Over the Past 10 Years
Min: 5.76  Med: 10.18 Max: 34.88
Current: 23.18
5.76
34.88
Forward P/E 16.81
ABT's Forward P/E is ranked higher than
85% of the 54 Companies
in the Global Medical Devices industry.

( Industry Median: 24.15 vs. ABT: 16.81 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 26.64
ABT's PE(NRI) is ranked higher than
51% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 26.92 vs. ABT: 26.64 )
Ranked among companies with meaningful PE(NRI) only.
ABT' s PE(NRI) Range Over the Past 10 Years
Min: 5.76  Med: 11.39 Max: 250.57
Current: 26.64
5.76
250.57
Price/Owner Earnings (ttm) 47.32
ABT's Price/Owner Earnings (ttm) is ranked lower than
69% of the 108 Companies
in the Global Medical Devices industry.

( Industry Median: 31.00 vs. ABT: 47.32 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ABT' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 4.53  Med: 8.70 Max: 1530
Current: 47.32
4.53
1530
P/B 2.66
ABT's P/B is ranked higher than
51% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 2.74 vs. ABT: 2.66 )
Ranked among companies with meaningful P/B only.
ABT' s P/B Range Over the Past 10 Years
Min: 1.39  Med: 2.22 Max: 3.34
Current: 2.66
1.39
3.34
P/S 2.75
ABT's P/S is ranked higher than
53% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.99 vs. ABT: 2.75 )
Ranked among companies with meaningful P/S only.
ABT' s P/S Range Over the Past 10 Years
Min: 0.96  Med: 1.65 Max: 6.27
Current: 2.75
0.96
6.27
PFCF 32.27
ABT's PFCF is ranked lower than
59% of the 95 Companies
in the Global Medical Devices industry.

( Industry Median: 29.37 vs. ABT: 32.27 )
Ranked among companies with meaningful PFCF only.
ABT' s PFCF Range Over the Past 10 Years
Min: 4.38  Med: 8.72 Max: 37.93
Current: 32.27
4.38
37.93
POCF 19.66
ABT's POCF is ranked lower than
51% of the 130 Companies
in the Global Medical Devices industry.

( Industry Median: 19.79 vs. ABT: 19.66 )
Ranked among companies with meaningful POCF only.
ABT' s POCF Range Over the Past 10 Years
Min: 3.82  Med: 6.56 Max: 23.11
Current: 19.66
3.82
23.11
EV-to-EBIT 22.05
ABT's EV-to-EBIT is ranked lower than
53% of the 167 Companies
in the Global Medical Devices industry.

( Industry Median: 20.28 vs. ABT: 22.05 )
Ranked among companies with meaningful EV-to-EBIT only.
ABT' s EV-to-EBIT Range Over the Past 10 Years
Min: -214.2  Med: 10.10 Max: 5414.3
Current: 22.05
-214.2
5414.3
EV-to-EBITDA 14.40
ABT's EV-to-EBITDA is ranked higher than
58% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 17.82 vs. ABT: 14.40 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.3  Med: 9.90 Max: 28.4
Current: 14.4
4.3
28.4
Shiller P/E 13.59
ABT's Shiller P/E is ranked higher than
84% of the 44 Companies
in the Global Medical Devices industry.

( Industry Median: 40.52 vs. ABT: 13.59 )
Ranked among companies with meaningful Shiller P/E only.
ABT' s Shiller P/E Range Over the Past 10 Years
Min: 9  Med: 12.53 Max: 18.1
Current: 13.59
9
18.1
Current Ratio 1.48
ABT's Current Ratio is ranked lower than
81% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.88 vs. ABT: 1.48 )
Ranked among companies with meaningful Current Ratio only.
ABT' s Current Ratio Range Over the Past 10 Years
Min: 0.75  Med: 1.39 Max: 2.36
Current: 1.48
0.75
2.36
Quick Ratio 1.15
ABT's Quick Ratio is ranked lower than
75% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. ABT: 1.15 )
Ranked among companies with meaningful Quick Ratio only.
ABT' s Quick Ratio Range Over the Past 10 Years
Min: 0.55  Med: 1.10 Max: 2.07
Current: 1.15
0.55
2.07
Days Inventory 110.88
ABT's Days Inventory is ranked higher than
61% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: 136.99 vs. ABT: 110.88 )
Ranked among companies with meaningful Days Inventory only.
ABT' s Days Inventory Range Over the Past 10 Years
Min: 76.02  Med: 88.71 Max: 117.9
Current: 110.88
76.02
117.9
Days Sales Outstanding 61.39
ABT's Days Sales Outstanding is ranked higher than
62% of the 271 Companies
in the Global Medical Devices industry.

( Industry Median: 68.67 vs. ABT: 61.39 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.14  Med: 69.20 Max: 77.62
Current: 61.39
61.14
77.62
Days Payable 43.65
ABT's Days Payable is ranked lower than
66% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 61.70 vs. ABT: 43.65 )
Ranked among companies with meaningful Days Payable only.
ABT' s Days Payable Range Over the Past 10 Years
Min: 35.38  Med: 39.77 Max: 45.11
Current: 43.65
35.38
45.11

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.67
ABT's Dividend Yield is ranked higher than
82% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 1.72 vs. ABT: 2.67 )
Ranked among companies with meaningful Dividend Yield only.
ABT' s Dividend Yield Range Over the Past 10 Years
Min: 1.41  Med: 5.11 Max: 7.9
Current: 2.67
1.41
7.9
Dividend Payout 0.69
ABT's Dividend Payout is ranked higher than
99% of the 113 Companies
in the Global Medical Devices industry.

( Industry Median: 0.37 vs. ABT: 0.69 )
Ranked among companies with meaningful Dividend Payout only.
ABT' s Dividend Payout Range Over the Past 10 Years
Min: 0.34  Med: 0.49 Max: 6.5
Current: 0.69
0.34
6.5
Dividend Growth (3y) -21.80
ABT's Dividend Growth (3y) is ranked lower than
90% of the 77 Companies
in the Global Medical Devices industry.

( Industry Median: 9.10 vs. ABT: -21.80 )
Ranked among companies with meaningful Dividend Growth (3y) only.
ABT' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -31.2  Med: 9.00 Max: 12.4
Current: -21.8
-31.2
12.4
Forward Dividend Yield 2.81
ABT's Forward Dividend Yield is ranked higher than
79% of the 164 Companies
in the Global Medical Devices industry.

( Industry Median: 1.73 vs. ABT: 2.81 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.06
ABT's Yield on cost (5-Year) is ranked lower than
70% of the 194 Companies
in the Global Medical Devices industry.

( Industry Median: 1.83 vs. ABT: 1.06 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ABT' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.56  Med: 2.03 Max: 3.13
Current: 1.06
0.56
3.13
3-Year Average Share Buyback Ratio 2.20
ABT's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: -3.30 vs. ABT: 2.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.8  Med: -0.10 Max: 2.2
Current: 2.2
-0.8
2.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 10.04
ABT's Price/Tangible Book is ranked lower than
82% of the 268 Companies
in the Global Medical Devices industry.

( Industry Median: 3.76 vs. ABT: 10.04 )
Ranked among companies with meaningful Price/Tangible Book only.
ABT' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.1  Med: 9.28 Max: 466.55
Current: 10.04
3.1
466.55
Price/Projected FCF 0.92
ABT's Price/Projected FCF is ranked higher than
83% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 2.06 vs. ABT: 0.92 )
Ranked among companies with meaningful Price/Projected FCF only.
ABT' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.36  Med: 0.82 Max: 1.93
Current: 0.92
0.36
1.93
Price/Median PS Value 1.67
ABT's Price/Median PS Value is ranked lower than
83% of the 268 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. ABT: 1.67 )
Ranked among companies with meaningful Price/Median PS Value only.
ABT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.6  Med: 1.13 Max: 3.64
Current: 1.67
0.6
3.64
Price/Graham Number 3.45
ABT's Price/Graham Number is ranked lower than
69% of the 137 Companies
in the Global Medical Devices industry.

( Industry Median: 2.06 vs. ABT: 3.45 )
Ranked among companies with meaningful Price/Graham Number only.
ABT' s Price/Graham Number Range Over the Past 10 Years
Min: 1.11  Med: 2.28 Max: 20.86
Current: 3.45
1.11
20.86
Earnings Yield (Greenblatt) (%) 4.56
ABT's Earnings Yield (Greenblatt) (%) is ranked higher than
72% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. ABT: 4.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ABT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 9.70 Max: 18.5
Current: 4.56
0.1
18.5
Forward Rate of Return (Yacktman) (%) 2.65
ABT's Forward Rate of Return (Yacktman) (%) is ranked lower than
63% of the 115 Companies
in the Global Medical Devices industry.

( Industry Median: 7.22 vs. ABT: 2.65 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ABT' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -18.7  Med: 15.20 Max: 31.9
Current: 2.65
-18.7
31.9

More Statistics

Revenue (TTM) (Mil) $20,393
EPS (TTM) $ 1.62
Beta1.49
Short Percentage of Float3.67%
52-Week Range $36.00 - 51.74
Shares Outstanding (Mil)1,469.15

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 20,906 23,781 23,047
EPS ($) 2.12 2.42 2.68
EPS w/o NRI ($) 2.12 2.42 2.68
EPS Growth Rate
(3Y to 5Y Estimate)
8.99%
» More Articles for NYSE:ABT

Headlines

Articles On GuruFocus.com
Becton Dickinson: 19% EPS Growth With Good Dividends Jun 26 2016 
Opinions Differ on Abbott Deal to Acquire St. Jude's Medical Jun 18 2016 
This Health Care Dividend Aristocrat Will Profit From Old Age – Globally May 29 2016 
Ackman Selling Zoetis, But Other Firms Are Jumping In May 10 2016 
Bearish Sentiment in Becton Dickinson's Stock Apr 27 2016 
Stocks Murray Stahl Bought for Past 2 Quarters Apr 26 2016 
A Cheap Dividend Aristocrat Yielding Over 4% Mar 02 2016 
Valeant's Share Price Continues to Decline Feb 05 2016 
Abbott a Dividend Aristocrat Stock Propelled by Emerging Markets Dec 11 2015 
Baxalta Vs. AbbVie: Biopharma Spin-Off Battle Aug 20 2015 

More From Other Websites
ETF’s with exposure to Abbott Laboratories : June 27, 2016 Jun 27 2016
Why You Shouldn’t Talk About Your Old Job in a New Role Jun 26 2016
Abbott Laboratories :ABT-US: Earnings Analysis: Q1, 2016 By the Numbers : June 24, 2016 Jun 24 2016
Abbott Laboratories breached its 50 day moving average in a Bullish Manner : ABT-US : June 24, 2016 Jun 24 2016
Abbott Laboratories : ABT-US: Dividend Analysis : July 15th, 2016 : By the numbers : June 23, 2016 Jun 22 2016
Cramer: Without business from Apple, it's treading water Jun 22 2016
Abbott Hosts Conference Call for Second-Quarter Earnings Jun 22 2016
How Waltham's PerkinElmer became the world leader in newborn screening Jun 21 2016
Abbott Labs upgraded by Edward Jones Jun 21 2016
Epizyme Offers Early Data on Non-Hodgkin Lymphoma Drug Jun 20 2016
Opinions Differ on Abbott Deal to Acquire St. Jude's Medical Jun 18 2016
Abbott Laboratories (ABT) Is in Oversold Territory: What's Next? Jun 17 2016
Why M&A Deals Can Strengthen Moats Jun 16 2016
Abbott Labs (ABT) Reports Positive Data on FreeStyle Libre Jun 14 2016
Abbott Laboratories (ABT) Stock Down, Jefferies Raises Price Target Jun 14 2016
Abbott Announces Positive Results from Groundbreaking Study of FreeStyle® Libre System for People... Jun 13 2016
Former Fed President: All My Very Rich Friends Are Holding a Lot of Cash Jun 13 2016
Abbott Declares 370th Consecutive Quarterly Dividend Jun 10 2016
7 Medical Stocks to Buy with Market-Beating Yields Jun 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)